Even genes with a more modest change in expression could have a profound anti-cancer effect; for example, Interferon Regulatory Factor 4 (IRF4), an important NF-κB-activated regulator of immune system development and the innate immune response [113], also plays an essential role in many lymphoid malignancies, and knockdown of its expression by only 50% is lethal to multiple myeloma cells [114, 115]. Here, NFKB1 is linked to AL amyloidosis.